The FDA is picky about drug names. It's been known to reject brand monikers because they're too similar to others already out there in the market, worried that harried physicians and pharmacists might accidentally give patients the wrong one.
The effects of a nasty flu season may wear off quickly, but two newly launched breast cancer drugs should help to keep the oncology increases coming.
Roche, whose patents have been under attack in India, is moving forward with plans to manufacture some drugs in the country, indicating it will drop the prices by as much as 50%, even as it faces a new threat from India's compulsory license law.
Roche sales grew last year. So did core earnings, by a healthy 10%. But the Swiss drugmaker's executives weren't jumping for joy. In fact, they were quite measured in their outlook for 2013, predicting sales growth of about 4%, along the same lines as its 2012 results.
Targeted drugs are becoming the focus of a growing number of companies, and manufacturers are responding by building more antibody drug conjugate manufacturing capacity.
India is taking another swipe at Big Pharma. Three swipes, in fact: The government has started the process of granting three more compulsory licenses, this time on cancer treatments from Roche and Bristol-Myers Squibb. That means cheap copies of the on-patent drugs could soon hit the Indian market.
Roche tightened its lock on the breast cancer treatment market, and its expectations for many more billions of dollars in annual revenue, when an EU panel gave thumbs up for approval of Perjeta.
Roche moved a step closer to adding another gem to its crown as the leading provider of therapies against a form of breast cancer. European officials backed approval of the Swiss drug giant's Perjeta (pertuzumab) for use as part of a combo attack on HER2-positive breast cancers.
While other drugmakers cut prices, set up access plans or wrangle with the Chinese government to sell products in that country, Roche ($RHHBY) is taking a more indirect tack. As Bloomberg reports, the Swiss drugmaker has teamed up with the reinsurer Swiss Re to sell private insurance to middle-class Chinese. That way, more patients can afford to use the company's pricey cancer drugs.
Did Roche ($RHHBY) bungle tens of thousands of adverse-event reports? European regulators aim to find out. The European Medicines Agency says it has started an "infringement procedure" against the Swiss drugmaker, to probe allegations that it dragged its feet on reporting potential side effects.